HomeCompareBNOEF vs CL

BNOEF vs CL: Dividend Comparison 2026

BNOEF yields 33333.33% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOEF wins by $8.428195308647591e+21M in total portfolio value
10 years
BNOEF
BNOEF
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.428195308647591e+21M
Annual income
$8,378,748,509,141,157,000,000,000,000.00
Full BNOEF calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — BNOEF vs CL

📍 BNOEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOEFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOEF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNOEF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOEF
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,121,936,232,769,983,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, BNOEF beats the other by $7,121,936,232,769,983,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOEF + CL for your $10,000?

BNOEF: 50%CL: 50%
100% CL50/50100% BNOEF
Portfolio after 10yr
$4.2140976543237957e+21M
Annual income
$4,189,374,254,570,578,700,000,000,000.00/yr
Blended yield
99.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

BNOEF
No analyst data
Altman Z
-5.0
Piotroski
6/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOEF buys
0
CL buys
0
No recent congressional trades found for BNOEF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOEFCL
Forward yield33333.33%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$8.428195308647591e+21M$40.8K
Annual income after 10y$8,378,748,509,141,157,000,000,000,000.00$5,401.96
Total dividends collected$8.424943808765552e+21M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BNOEF vs CL ($10,000, DRIP)

YearBNOEF PortfolioBNOEF Income/yrCL PortfolioCL Income/yrGap
1← crossover$3,344,033$3,333,333.33$11,012$312.01+$3.33MBNOEF
2$1,045,333,048$1,041,754,932.50$12,196$412.95+$1045.32MBNOEF
3$305,463,295,767$304,344,789,404.97$13,599$549.66+$305463.28MBNOEF
4$83,443,192,327,233$83,116,346,600,762.75$15,288$736.64+$83443192.31MBNOEF
5$21,308,754,850,592,396$21,219,470,634,802,260.00$17,353$995.28+$21308754850.58MBNOEF
6$5,087,082,937,849,453,000$5,064,282,570,159,319,000.00$19,926$1,357.80+$5087082937849.43MBNOEF
7$1,135,355,897,925,379,400,000$1,129,912,719,181,880,500,000.00$23,194$1,873.82+$1135355897925379.50MBNOEF
8$236,895,694,937,506,160,000,000$235,680,864,126,726,020,000,000.00$27,439$2,621.52+$236895694937506176.00MBNOEF
9$46,211,962,155,546,610,000,000,000$45,958,483,761,963,480,000,000,000.00$33,088$3,727.38+$46211962155546607616.00MBNOEF
10$8,428,195,308,647,591,000,000,000,000$8,378,748,509,141,157,000,000,000,000.00$40,806$5,401.96+$8.428195308647591e+21MBNOEF

BNOEF vs CL: Complete Analysis 2026

BNOEFStock

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOEF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this BNOEF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOEF vs SCHDBNOEF vs JEPIBNOEF vs OBNOEF vs KOBNOEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.